available scientific background. The demands and options for collagenase in future treatment regimens for extensile Dupuytren contractures are discussed.
contractures can be released with single injections on monthly intervals, to address one joint contracture at a time. However, in hands affected with Dupuytren contractures to the extent that the patient calls for treatment, most often more than one joint is involved. In surgical treatment options all contracted joints are addressed in a single procedure.
Nevertheless, extensile surgery withholds inherent risks of complications and intense rehabilitation. Today, the minimally-invasive method with enzymatic fasciotomy by collagenase injection has demonstrated reliable outcomes with few morbidities and early recovery. However, single-site injection is todays' standard procedure and multiple joints are addressed in several sessions with monthly intervals. This triggers a longer recovery and treatment burden in severely affected hands even though surgery is avoided. Therefore, further treatment modalities of collagenase use are explored. Adjustments in the treatment regimes' flexibility and collagenase injections addressing more than one joint contracture simultaneously will improve the burden of multiple sessions and, therefore, enzymatic fasciotomy may become the preferred method in more extensile Dupuytren contractures. In this independent review, the challenge of Dupuytren disease affecting a single versus multiple joints is presented. The pros and cons of collagenase use are weighed, founded by the Electronic supplementary material The online version of this article (doi:10.1007/s40744-016-0027-1) contains supplementary material, which is available to authorized users.
INTRODUCTION
Dupuytren contracture is a highly prevalent hand affection in which contracted fingers compromise hand function. In a recent meta-analysis prevalence up to 30% in the Western countries was reported, increasing with age [24] . Asymptomatic palmar fibrosis is more common than overt contractures, which require treatment [15] . The standard treatment has been fasciotomy or fasciectomy ever since Baron Guillaume Dupuytren introduced cutting the strands in his the public sessions at the Hotel Dieu in Paris in 1831 [1] . Since then, the pathology has been extensively studied, with historical milestones as the histology stages of Luck in 1959 [27] the identification of the myofibroblast by Gabbiani in 1972 [18] . It is the collagen production of these myofibroblast that holds the finger contractures. This collagen is found more in the cords than in the nodules, which contain mostly myofibroblasts [46] . Articles that present the results of scientific levels 3 and higher (Centre of Evidence-Based Medicine, CEBM) that address the questions of this independent review (goals) were included.
These goals were mentioned above at the last paragraph of the introduction and focus on the need, the benefits, possible risks and assessment of flexible regimens and multiple joint collagenase treatment options in severely affected hands with Dupuytren disease. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by the author.
RESULTS
On the prevalence of multiple joint affection in 
DISCUSSION

Collagenase in Dupuytren: Current State of the Art and Encountered Challenges
Yet incurable, treatment of Dupuytren disease is primarily focused on contracture release to regain finger motion and restore hand function. In the last decade, non-surgical collagenase treatment removed the monopoly of cutting or removing the strands that cause the contractures. The strength of this innovative treatment method is that surgery is avoided, recovery is fast, and the outcome is reliable, with a lower degree of recurrence than needle fasciotomy [33] . The clinical outcome is comparable with surgery (fasciectomy), but collagenase treatment provides a more rapid recovery and is associated with fewer serious adverse events [37, 38, 49] .
However, a weakness of the collagenase injection technique is the limit of single joint treatment in one setting with monthly interval repeats if needed to treat more joint contractures.
This single-shot injection technique was introduced mostly due to security measures. Toxic dosage limits were set low as a precaution and injection sites were limited to prevent severe immune response such as swelling, hematoma, and lymfangitis.
Treatment Regimen and Its Limits
Collagenase treatment is usually performed on an outpatient basis. The patient receives his collagen injection on the first day. The second day he returns for a finger manipulation in an effort to break the strands by forcefully extending the finger (usually under local anesthesia) and fit the extension splint. The hand will typically show edema to some extent for 5-10 days; a certain amount of pain and hindrance is expected for about 2 weeks [3] .
After care is focused on the recovery of full range of finger motion, which rarely indicates physiotherapy. A night-time splint to maintain full extension for at least 3 months is advised. Collagenase injections need to be planned strategically. The injection is performed on the first day and as prescribed, 
Collagenase in Severe Dupuytren
Contractures: Pushing Boundaries
Experience with the collagenase treatment is rapidly increasing. This is reflected in more efficient treatment regimens. First, the organizational issue of having 24 h in between injection and manipulation has been modified.
Mickelson et al. [32] demonstrated in 2014 an optional time span of 7 days in between both sessions without compromising efficiency [23] .
The finger extension procedure can be performed the next day or on any occasion within 1 week after the injection, whichever is more convenient [32] . Second, the surgeons experience has increased efficiency of the procedures. Peimer et al. [35] demonstrated that the number of injections per treated joint significantly decreased. In the registration trials, 1.7 injections per joint were required and after 1 year of use, this was reduced to a maximal efficiency of 1.08 injections [35] . More recent data confirmed that most treated joints now require only one injection [48] .
However, Coleman et al. [10, 11] demonstrated that many patients present with more than one joint affected and therefore require multiple injections. They calculated a mean (standard deviation) number of affected joints of 3 ± 2.2 in their intended to treat population [11] . Multiple ray involvement is seen in more than half of the hands [21, 25] .
This means that in the current algorithm of single joint treatment with monthly intervals between injections, the majority of patients will need to undergo multiple sessions in several months. This withholds a lengthy treatment and recovery burden to the patient. The efficiency of collagenase in fixed proximal interphalangeal joint contractures is equal if a second injection session is needed after initial metacarpophalangeal treatment, but the overall treatment is longer [21] . This motivated clinical researchers to explore the option of concurrent multiple strand collagenase treatment in Dupuytren disease to fulfill the important unmet need in the commonly seen multiple digit Dupuytren contractures.
Recent outcome studies report promising results. Gaston et al. [20] demonstrated successful concurrent double-dose injections in one or two cords in a single session. Efficacy was comparable with earlier reports and no adverse events were reported, with the exception of skin laceration in 22% [29] . Atroshi et al. [2] reported promising outcomes in higher dosage injections with a technique modification allowing multiple joint corrections in a single session.
Again, more skin tears were encountered (in 40%). It is unclear whether the double dose is the cause of these skin lacerations or rather the more significant contracture release is. Hence, skin tears are also seen in needle fasciotomy, without enzyme injection in 27% of the patients [39] . Another option is to use the whole bottle of collagenase clostridium histolyticum (0.78 mg instead of 0.58 mg): this was reported by Verheyden [45] as another efficient way to increase the dosage and safely treat multi-cord affections in a single session in 144 patients.
However, if multiple strand treatment is considered, risks and benefits need to be outweighed and scientific support for this clinical research needs to be explored.
Risks
The risks of injecting collagenase are predominantly injection-related and transient: skin rupture, tendon rupture, swelling and edema, hematoma, pain, lymfangitis, fever, and pruritus [36] . Severe allergic reactions and anaphylactic shock are possible but not one case has been reported up until now. On the other hand, antibodies to collagenase may develop after several treatments, raising concerns about safety and efficacy as a result of sensitization from repeated exposures. The development of recombinant enzyme treatment methods was initially introduced for treating lysosomal storage disorders. Now, the collagen-based disorder of Dupuytren disease is treated with the collagenase clostridium hystolyticum.
Although enzyme treatment may hence carry the risk of immunological response certainly in repeated long-term treatment logarithms, safety findings and adverse event reports and surely problems of immunogenicity remain mild in general [5] . Gajendran et al. [19] reported good results in a patient receiving 12 dosages in 15 injections over a 4-year period in 2014. They compare the evolution and increasing knowledge with the botulinum toxin injection experience and future adjustments of the formula to prevent blocking antibodies in some patients may be required 1 day.
Benefits
If ascertained safe and efficient, treating two joints simultaneously with collagenase injections in a single session will obviously benefit the patient and treating surgeon in different ways. First, overall treatment time will be reduced significantly. Treating two joints in one session, means restoring motion in at least one complete finger in a maximum of one treatment week, where in two monthly interval sessions, it would mean a total treatment time of four to 6 weeks. What is more, optimized injection techniques add to this benefit. For instance, a y-type strand causing more than one finger contracture can be solved with strategic injections with even more extensile corrections, in which more fingers (including two to even six joints) are addressed in a single treatment session [30] . This obviously precludes a lower working incapacity for the patient with a lower healthcare cost, implies less time to treat, and higher patient satisfaction with immediate results [10, 11] . On top of fewer treatment sessions and faster rehabilitation, one must also consider the benefit in more efficient orthotic devices without secondary adjustments, since every session changes the configuration of the hand [31] . Furthermore, if therapy is indicated after collagenase treatment, as required in more severe contractures mostly of interphalangeal joints, the rehabilitation period will equally be reduced as overall injection sessions [42] .
Last, the anatomical restriction of injection sites that excludes the distal interphalangeal joint contractures was sporadically challenged in off-label use in limited cases by different surgeons, including the author. These more rare contractures can be successfully addressed with a 0.1 mg injection in the lateral cord at the proximal interphalangeal (PIP) joint. Obviously, the increasing efficiency in collagenase injections with fewer treatment sessions and increased gain in finger motion will benefit more patients suffering from severe Dupuytren disease. This evolution may therefore reduce the need for elaborate surgery with its inherent risks in the more challenging Dupuytren contractures.
Collagenase in Future Treatment Regime for Dupuytren Disease
Collagenase now has become common practice in numerous hand surgery practices for Dupuytren treatment and its position in the regimen is yet evolutionary [20, 47] . The optimization of collagenase injections in Dupuytren contractures may reduce surgery even more in the overall treatment regime. Collagenase treatment can be extended to more severe Dupuytren disease. In severely affected hands, extensile surgery carries a higher risk for complications in up to 46% of the patients [8, 12, 14, 26, 28] . Digital nerve or artery injuries are even 10 times more common in recurrent disease than in primary surgery [12, 17, 41] .
Local health economic differences may influence treatment regimes, although generally the total social cost of collagenase treatment of Dupuytren contracture is lower than surgery [6, 9, 13, 31, 38, 40] . In countries such as Belgium, where healthcare reimbursement is limited to a number of injections per hand after simple cost-benefit analysis, the optimization of collagenase injection techniques is essential to offer more patients the option of enzymatic fasciotomy to avoid or postpone surgery [38] . Recurrence risk after collagenase treatment is not lower than in surgery, with similar reports varying between 4% after 1 year to 47% in 5 years. These results are comparable with recurrence reports in surgical outcome studies with a variety of recurrence reports ranging from 0 to 71%, depending on definition and time of follow-up [7, 29, 34] . Surgical technique does not influence recurrence rates, although needle fasciotomy has a particularly high recurrence [7, 44] . In recurrence after collagenase treatment, repeat injections or even surgery remain viable options to treat recurrent contractures [16, 19] . 
CONCLUSIONS
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